A vast majority of chronic myeloid leukemia (CML) cases are caused by the Philadelphia translocation, which results in a constitutively active BCR-Abl representing the paradigm of therapeutic intervention using specific kinase inhibitors [20, 33]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.